Premium
Protein‐protein interactions as antibiotic targets: A medicinal chemistry perspective
Author(s) -
Cossar Peter J.,
Lewis Peter J.,
McCluskey Adam
Publication year - 2020
Publication title -
medicinal research reviews
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.868
H-Index - 130
eISSN - 1098-1128
pISSN - 0198-6325
DOI - 10.1002/med.21519
Subject(s) - antibiotics , small molecule , drug , computational biology , antimicrobial , drug discovery , drug development , immune system , chemistry , biology , medicine , pharmacology , bioinformatics , microbiology and biotechnology , immunology , biochemistry
Abstract There are 27 small molecule protein‐protein interaction (PPI) modulators in Phase I, II, and III clinical trials targeting cancer, viruses, autoimmune disorders, and as immune suppression agents. Targeting PPIs as an antibiotic drug discovery strategy remains in relative infancy by comparison. However, a number of molecules are in development which target PPI within the replisome, divisome, transcriptome, and translatome are showing significant promise at the medicinal chemistry stage of drug development. Hence, the success of future PPI agents as antibiotics will build upon the techniques and design strategies of these molecules.